Lipid-conjugated Ru(iii) complexes as inhibitors of pathological peptide aggregation in neurodegenerative disorders
Claudia Riccardi, Ettore Napolitano, Chiara Platella, Andrea Conte, Simona Paladino, Domenica Musumeci, Daniela Montesarchio · 2026
Read Lipid-conjugated Ru(iii) complexes as inhibitors of pathological peptide aggregation in neurodegenerative disorders by Claudia Riccardi, Ettore Napolitano, Chiara Platella, Andrea Conte, Simona Paladino, Domenica Musumeci, Daniela Montesarchio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13456193.txt.
Description
Claudia Riccardi and six colleagues test, in a 2026 chemistry study, rust-colored ruthenium compounds fitted with fatty tails against the protein clumping behind brain diseases. Clumped peptides drive Alzheimer and Parkinson diseases and prion disorders. Two ruthenium drugs first built for cancer had already shown anti-clumping promise, so the team tried a cousin compound and its fat-tailed versions.
Two tailed versions, named for their myristic and palmitic tails in the study, stopped amyloid peptide clumping at low doses, around five micromolar. Closer study showed the metal anchors to histidine spots near the peptide's start. In human nerve-like cells, the compounds caused no meaningful harm at the doses that blocked clumping. The authors present the fat-tailed design as a route to brain-friendly anti-aggregation drugs, marrying the metal's grip with tails that may aid delivery.
Catalog record
| CREATOR | Claudia Riccardi, Ettore Napolitano, Chiara Platella, Andrea Conte, Simona Paladino, Domenica Musumeci, Daniela Montesarchio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |